Physician

Julio Paolo Zavala, MD

According to 2025 Medicare claims, Julio Zavala, MD (NPI: 1649401589) practices nephrology in the Laredo, TX market, with the plurality of this provider's patient population coming from Webb, TX. This provider's primary affiliated billing organization is LAREDO NEPHROLOGISTS PLLC (NPI: 1295075927; TIN: 462049200) and primary practice location at 78041-5474.

Zavala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 369 traditional Medicare patients, billed 1,777 HCPCS/CPT codes, and received $183,619 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,172 prescription claims across 236 beneficiaries totaling $351,429 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). 2020 DME data shows 98 claims. Open Payments data shows 5 records totaling $189. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $331,796 to $183,619. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $582,565 and ending at $351,429. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	618	3,349	$331,796
2016	783	4,176	$379,495
2017	837	3,987	$356,311
2018	777	4,252	$470,434
2019	902	4,110	$430,007
2020	757	2,567	$297,061
2021	339	1,470	$146,494
2022	281	1,315	$132,528
2023	388	1,849	$203,147
2024	369	1,777	$183,619

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	764	$582,565
2016	332	1,317	$215,503
2017	378	1,305	$415,769
2018	322	1,215	$424,114
2019	359	1,349	$539,280
2020	305	1,170	$446,184
2021	159	582	$78,691
2022	144	771	$117,731
2023	215	797	$163,221
2024	236	1,172	$351,429

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	25	$1,400
2016	N/R	12	$565
2017	N/R	26	$694
2018	N/R	41	$1,183
2019	N/R	61	$1,984
2020	N/R	98	$4,006
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	95	116	$126
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	85	276	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	66	121	$78
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	161	475	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	83	175	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	36	1,592	$46,463
Farxiga	Dapagliflozin Propanediol	50	2,370	$40,818
Velphoro	Sucroferric Oxyhydroxide	14	540	$39,399
Jardiance	Empagliflozin	33	1,362	$27,877
Lokelma	Sodium Zirconium Cyclosilicate	14	819	$17,597

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$189	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Julio Paolo Zavala, MD?

Tedicare shows public-source Medicare data for Julio Paolo Zavala, MD (NPI 1649401589), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Julio Paolo Zavala, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Julio Paolo Zavala, MD?

Julio Paolo Zavala, MD is linked to LAREDO NEPHROLOGISTS PLLC (billing NPI 1295075927) in the available physician profile data.

Does Julio Paolo Zavala, MD have Open Payments data?

Julio Paolo Zavala, MD has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.